Transpharmation Ltd.

TRANSPHARMATION Ltd is a preclinical CRO spun out of GlaxoSmithKline Pharmaceuticals (GSK) in 2010. Our mission is to be regarded as the leading CRO for cross-species and cross-therapeutic area in translational pharmacology from bench to bedside. Following the transfer of key personnel, assay know-how and equipment from GSK, TRANSPHARMATION has enjoyed unprecedented growth in its preclinical and experimental medicine service offering. This growth has been driven by highly characterised assays sensitive to clinical gold standards, state of the art technology and human tissue assays. With models spanning rodents, dogs and non-human primates through to humans, our core therapeutic expertise includes: EEG, cognition (Alzheimer's and Parkinson's disease), epilepsy, pain, neurodegeneration, neuroinflammation and anxiety/mood disorders (including treatment-resistant depression, sleep disorders and schizophrenia), together with a biomarker platform, PD/PK studies and human tissue capabilities. In addition, Transpharmation has a significant internal research programme centred on a strategy to better understand and stratify responders and non-responders to clinical gold standards based on the detection of neurophysiological and molecular biomarkers. Transpharmations' HQ is located at The London Bioscience Innovation Centre, and R&D facilities are located at: Building 500, Discovery Park (Kent-UK), Trinity College Dublin - Institute of Neuroscience (Ireland) and Faculty of Veterinary Medicine University of Warmia & Mazury in Olsztyn (Poland).